Natera, Inc. (NASDAQ:NTRA) Insider Sells $149,837.04 in Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 1,026 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $146.04, for a total value of $149,837.04. Following the completion of the transaction, the insider now directly owns 144,782 shares in the company, valued at $21,143,963.28. This represents a 0.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, March 5th, Solomon Moshkevich sold 6,000 shares of Natera stock. The shares were sold at an average price of $143.29, for a total value of $859,740.00.
• On Wednesday, January 29th, Solomon Moshkevich sold 5,201 shares of Natera stock. The shares were sold at an average price of $165.87, for a total value of $862,689.87.
• On Wednesday, January 22nd, Solomon Moshkevich sold 24,861 shares of Natera stock. The shares were sold at an average price of $164.97, for a total value of $4,101,319.17.

Natera Price Performance

NTRA traded up $1.52 during trading on Friday, reaching $151.15. The stock had a trading volume of 3,420,538 shares, compared to its average volume of 1,339,250. The stock has a market cap of $20.43 billion, a PE ratio of -85.88 and a beta of 1.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a one year low of $83.13 and a one year high of $183.00. The business has a 50-day moving average of $161.23 and a 200-day moving average of $150.01.

Remove Ads

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $476.10 million for the quarter, compared to analysts' expectations of $447.91 million. As a group, equities research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on NTRA. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $180.00 target price on shares of Natera in a research report on Wednesday, February 26th. Robert W. Baird boosted their target price on Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. StockNews.com raised Natera from a "sell" rating to a "hold" rating in a research report on Wednesday. Royal Bank of Canada began coverage on Natera in a research report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 target price for the company. Finally, Barclays began coverage on shares of Natera in a report on Thursday, January 23rd. They issued an "overweight" rating and a $200.00 price target on the stock. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $178.12.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of Natera by 7.7% during the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock valued at $1,949,697,000 after buying an additional 879,463 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Natera by 134.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after purchasing an additional 3,871,862 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Natera by 43.7% during the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock worth $1,060,836,000 after purchasing an additional 2,036,396 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Natera by 15.7% during the fourth quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock worth $512,898,000 after purchasing an additional 439,778 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of Natera by 3.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company's stock worth $315,194,000 after purchasing an additional 85,236 shares during the period. 99.90% of the stock is owned by institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.